Fibromyalgia and back pain: features

Fibromyalgia is a chronic, generalized pain that lasts at least 3 months, affects at least 4 of 5 body regions, and is accompanied by severe fatigue, sleep disturbances, and cognitive symptoms ("fibrofog"). It is classified as a chronic primary pain disorder: that is, the pain is disproportionate to the visible tissue damage, and central pain-processing mechanisms play a key role. Fibromyalgia is not a "psychological fiction," but a biologically explainable condition with altered nociception and sensitization. [1]

Back pain in these patients is a common part of the "mosaic," but it differs in nature from localized myofascial pain: it is less confined to a single muscle, more diffuse, characterized by pronounced morning fatigue and instability of symptoms throughout the day. An important clinical detail: the absence of obligatory trigger nodules on palpation does not rule out fibromyalgia—in fact, their absence in the presence of generalized pain suggests this diagnosis. [2]

Modern diagnostic criteria allow fibromyalgia to be diagnosed when thresholds for the pain prevalence index and symptom severity scale are met, without the "mandatory" exclusion of all other conditions, although a minimum of "reasonable" tests remains. This significantly shortens the path to diagnosis and a workable treatment plan. [3]

Table 1. Fibromyalgia and myofascial pain: what's the difference?

Sign	Fibromyalgia	Myofascial pain
Pain Map	Generalized (≥4 of 5 regions)	Local/regional
Trigger points	Usually there are no specific local "nodules"	There are often palpable triggers
Leading symptoms	Fatigue, sleep disturbances, fibro fog	Painful muscle "tourniquet", limited mobility
Mechanisms	Central sensitization, impaired pain modulation	Local overload of muscles and fascia
Response to treatment	A combination of education, movement, psychotherapy, and targeted medications	Local rehabilitation, work with overload, sometimes injections

Terminology and place of diagnosis among chronic pain

Internationally, fibromyalgia is classified as a chronic primary pain disorder. This is important because the management strategy shifts from "finding the cause" to restoring function, improving sleep and emotions, and regulating the "pain processing system." NICE emphasizes that a personalized plan that integrates education, exercise, psychological approaches, and limited pharmacotherapy is helpful. [4]

The 2016 ACR criteria replaced the old "pain points": diagnosis is now based on the pain prevalence index (WPI) and symptom severity scale (SSS), with pain requiring generalization and a duration of ≥3 months. The diagnosis can be made in the presence of other conditions if the criteria are met and another pathology does not fully explain the symptoms. [5]

This isn't a "rule-at-all-costs" diagnosis. It's about sensible screening for common mimics (hypothyroidism, inflammatory diseases, deficiencies), but without a cascade of unnecessary imaging and tests. This approach reduces years of wandering around offices and offers the chance to start effective treatments early. [6]

Table 2. ACR 2016 diagnostic criteria (simplified)

Parameter	Threshold
Pain Prevalence Index (WPI)	≥7 with SSS ≥5 or 4-6 with SSS ≥9
Generalized pain	In ≥4 of 5 regions (chest, jaw, and abdominal areas are not included in the “generalization” criterion)
Duration	≥3 months
Note	The diagnosis is made regardless of concomitant diagnoses if the criteria are met and there is no better explanation for the symptoms

Epidemiology

The average prevalence of fibromyalgia in the population is approximately 2-3%, more often in women (ratio approximately 3:1), but underrepresentation of men and variability in diagnostic criteria and cultural factors significantly influence estimates. Chronic widespread pain, similar in phenotype, occurs in approximately 10-12% of adults. [7]

Peak rates of symptomatic treatment occur between the ages of 30 and 60 years; comparable, but sometimes lower, estimates have been reported in Asian populations, which is attributed to differences in criteria and the propensity to report symptoms. Significant impacts on quality of life, employment, and social functioning are noted in all regions. [8]

Comorbidities are common: anxiety and depression, irritable bowel syndrome, tension headaches and migraines, and sleep disorders. These are not "companions," but important treatment targets that influence outcome. [9]

Table 3. Prevalence - what the surveys show

Source	Grade	Comment
StatPearls 2025	2-3% of adults	Women are more common, but the male phenotype is underestimated. [10]
Heidari 2017 Meta-Analysis	1.8% of the general population (variable)	Depends on criteria and sample. [11]
Chronic widespread pain (CWP)	≈10-12%	Phenotype similar to fibromyalgia. [12]
Men	Phenotype and small fiber neuropathy are described	Requires attention to diagnosis. [13]

Reasons

Fibromyalgia is not a "micro-muscle injury," but a disorder of pain processing: central sensitization, weakened descending inhibition, and an exaggerated response to stress signals. This explains the dissociation between pain intensity and the "purity" of the images. [14]

Some patients exhibit signs of small-fiber neuropathy (small-fiber neuropathy): decreased intraepidermal fiber density and impaired autonomic regulation. This is not universal, but it emphasizes the neurosensory nature of the syndrome. [15]

Exacerbation triggers include stress, lack of sleep, infection, overexertion/insufficiency, and sudden changes in activity. Therefore, the primary interventions are sleep, stress, moderate exercise, and recovery. [16]

Risk factors and associates

Female gender, family history of functional pain syndromes, history of trauma/stressful events, chronic sleep deprivation, comorbid anxiety and depression all increase the risk and worsen the prognosis without targeted intervention. [17]

Associated conditions include irritable bowel syndrome, headaches, temporomandibular joint dysfunction, and orthostatic intolerance. Identifying these helps make treatment plans realistic and multifactorial. [18]

In men, fibromyalgia is less commonly recognized, with symptoms often being misinterpreted as "myofascial" or "stress," leading to delayed diagnosis; targeted symptom collection and ACR scales help avoid this error. [19]

Pathogenesis

Key mechanisms: (1) increased central excitability (increased pain input), (2) weakening of descending antinociceptive control, (3) sensitization due to stress and sleep deprivation, (4) in some patients, small-fiber neuropathy. This creates a “loud pain amplifier” without visible tissue damage. [20]

Sleep disturbances and hyperarousal increase fatigue, "fibrofog," and daytime pain. Therefore, sleep management is not an "add-on" but rather a part of pathogenetic therapy. [21]

Symptoms

In addition to diffuse pain (including back pain), fatigue, unrefreshing sleep, cognitive "slowness," hypersensitivity to sensory stimuli, and intermittent orthostatic intolerance are typical. A significant proportion also experience anxiety/depression. Neurological deficits (persistent weakness, loss of reflexes) are not characteristic of fibromyalgia. [22]

The severity fluctuates from day to day; triggers include stress, sleepless nights, and a "surge" in activity. This is why patients benefit from "pacing" (activity dosing) and self-regulation skills. [23]

Classification, forms and stages

The following are used diagnostically: WPI (0-19), SSS (0-12), and the total severity index (FS 0-31). Clinically, phenotypes are distinguished with a predominance of pain, sleep, cognitive impairment, and "mixed" ones. The phenotype influences treatment priorities (e.g., an emphasis on sleep or on depression). [24]

The stages are arbitrary: rather, there are "waves" and "phases" of habits. The goal is not to "erase" pain to zero (which is often unattainable), but to restore function and quality of life and reduce the frequency of outbreaks. [25]

Complications and consequences

Fibromyalgia is associated with high medical costs and disability, particularly with a "fix-it" strategy and multiple unnecessary tests. Structuring care around quality of life and function changes the trajectory. [26]

Without sleep management, stress, and gradual progression, a vicious cycle of avoidance, deterioration of endurance, and worsening pain develops. Therefore, any plan includes education and behavioral approaches. [27]

When to see a doctor

Urgently - if there are any "red flags" of back pain: fever, unbearable pain at night, rapidly increasing weakness or numbness, impaired urinary/defecatory control, significant trauma, or a history of cancer. This requires immediate imaging and a different algorithm. [28]

Planned - if generalized pain, fatigue, and sleep disturbances persist for more than 3 months and limit daily life. It is especially important not to overlook inflammatory spondyloarthropathies in cases of inflammatory back pain (onset before age 45, morning stiffness >30 minutes, improvement with movement, HLA-B27, sacroiliitis on MRI). [29]

Table 4. Red flags and suspicion of another disease

Signal	What to suspect	Action
Fever, weight loss, night pain	Infection/tumor	Urgent visualization and oncosearch
Acute deficit in strength/sensation	Compression of the root/cauda equina	Emergency MRI
Onset of back pain before age 45 + inflammatory signs	Axial spondyloarthropathy	ASAS/ACR Algorithm for Imaging and Laboratory

Diagnostics

Step 1. Clinical interview and scales. We calculate the WPI (number of painful areas) and SSS (sleep, fatigue, cognitive symptoms, etc.), check the duration of symptoms and generalization (≥4 of 5 regions). This is the basis for diagnosis. [30]

Step 2. Minimal screening for mimics. Complete blood count, erythrocyte sedimentation rate/C-reactive protein (usually normal in fibromyalgia), thyroid-stimulating hormone; if there are specific complaints, targeted tests (deficiencies, celiac disease, etc.). Routine imaging is not required unless indicated. [31]

Step 3. Assess comorbidities. Sleep, mood, anxiety, orthostatic symptoms, irritable bowel syndrome—all influence treatment choice and prognosis. [32]

Step 4. Reassess the diagnosis in the event of an atypical course. If red flags or signs of an inflammatory back condition appear, the route is changed to a specialized one (rheumatology/neurology) with imaging according to ACR/ASAS criteria. [33]

Table 5. Diagnostic roadmap

Stage	What does it give?	When needed
WPI/SSS (ACR 2016)	Phenotype confirmation	Everyone at the starting line
Basic tests	Eliminate imitators	By default
Visualization	Only in case of “red flags”/suspected other pathology	According to the readings
Sleep/Mood Assessment	Selecting treatment priorities	To everyone

Differential diagnosis

Myofascial pain is localized, with trigger points identified. The pain is triggered by exertion on a specific muscle and is reduced by local rehabilitation. With fibromyalgia, the pain map is broader, triggers are optional, and comorbidities are more pronounced. [34]

Inflammatory spondyloarthropathies. Onset before age 45, morning stiffness, improvement with movement, HLA-B27, sacroiliitis on MRI. If suspected, a rheumatological evaluation is recommended to avoid labeling fibromyalgia as an inflammatory disease. [35]

Endocrine and systemic causes. Hypothyroidism, deficiencies, and inflammatory myopathies are excluded by targeted clinical screening rather than by "carpet bombing" tests. [36]

Table 6. What is fibromyalgia confused with - quick reference points

State	What does it suggest?	How to confirm
Myofascial pain syndrome	Local triggers, muscle "tourniquet"	The clinic, a response to local rehabilitation
Axial spondyloarthropathy	Inflammatory profile of back pain	ASAS criteria, MRI of the sacroiliac joints
Hypothyroidism/deficiencies	Systemic signs, laboratory clues	Targeted tests

Treatment

The foundation is education + movement + psychological approaches. NICE recommends a personalized activity program and psychological methods (cognitive behavioral therapy, acceptance and commitment therapy) for chronic primary pain (which includes fibromyalgia). This reduces catastrophizing, teaches "pacing," and restores control. [37]

Exercise is the basic "pill." Systematic reviews from 2023 to 2025 confirm the benefits of aerobic exercise, strength training for endurance, and mind-body exercises (tai chi, yoga). A practical prescription: 2-3 times a week for 25-40 minutes, starting with low intensity and gradually increasing over 6-12 weeks; a total volume of >100 minutes per week produces a noticeable effect on pain and quality of life. Tai chi, according to randomized trials, is comparable or superior to aerobic exercise in improving symptoms. [38]

Sleep is a "booster" of results. Sleep hygiene, behavioral techniques, and targeted pharmacotherapy as needed (below) improve daytime fatigue and reduce pain sensitivity. Without sleep, the effects of other interventions are diminished. [39]

Pharmacotherapy is supportive and targeted. The most consistent data are for antidepressants and neuromodulators: amitriptyline (especially for sleep disorders), duloxetine and milnacipran (for depression/fatigue and pain relief), and pregabalin (for selected patients with sleep disorders/allodynia). However, "major effects" are rare: systematic reviews show that significant pain relief occurs in approximately 1 in 10 adults over a period of 4-12 weeks. This requires honest discussion. [40]

What should NOT be started for chronic primary pain according to NICE: opioids, non-steroidal anti-inflammatory drugs, paracetamol, benzodiazepines, antipsychotics, ketamine, local anesthetic/steroid injections into "trigger zones", gabapentinoids (outside of studies). Exceptions are narrow and rare. [41]

Acupuncture: NICE allows one course as part of a non-pharmacological plan (limited by time and cost), but the effect is modest and not universal. TENS, ultrasound, and interference therapy are not recommended for chronic primary pain due to a lack of convincing benefit. [42]

Neuromodulation (tDCS). Meta-analyses from 2023-2025 show small-to-moderate reductions in pain and depression with appropriately selected protocols (cortical motor area and/or dorsolateral prefrontal cortex), especially when combined with education and exercise. This is currently a "second-tier" intervention for selected patients. [43]

Low-dose naltrexone (LDN) is experimental: A large randomized trial in 2024 found no benefit of 6 milligrams over placebo in pain reduction, although there are signs of improvement in cognitive complaints; reviews in 2024-2025 provide conflicting data. If discussed, this is done as a trial therapy with reasonable expectations and monitoring. [44]

Comprehensive multidisciplinary programs (education, exercise, psychotherapy, sleep management) offer the best chance for lasting change. They reduce dependence on medications and "medicalization" and restore function. [45]

Table 7. Treatment methods and strength of recommendations (by key sources)

Method	Role/Effect in 2025
Education + CBT/ACT	The basis for the management of chronic primary pain
Exercises (aerobic/strength/mind-body)	Moderate improvement in pain and quality of life with regularity
Sleep (behavioral approaches ± targeted medications)	The key to a sustainable effect
Duloxetine/milnacipran/amitriptyline/pregabalin	Helps some patients; the effect is usually moderate; discuss expectations
Acupuncture (one course)	Acceptable according to NICE, moderate short-term effect
tDCS	Promising as a complement to selected
NOT recommended to start (NICE)	Opioids, NSAIDs, paracetamol, TENS/ultrasound, trigger injections, benzodiazepines, antipsychotics

Table 8. Drugs: What to Expect and Who to Consider

Preparation	When appropriate	What to expect	Common effects
Amitriptyline (low dose)	Mainly sleep disturbances	Slight to moderate pain reduction, improved sleep	Dry mouth, drowsiness
Duloxetine	Depression/fatigue, pain	Improved pain, function, and mood in some patients	Nausea, sweating
Milnacipran	Emphasis on fatigue/pain	Similar to duloxetine in profile	Tachycardia, nausea
Pregabalin	Allodynia, sleep disturbances	Pain reduction/sleep improvement in some patients	Drowsiness, weight gain
LDN (experiment)	After informed consent	Results are inconsistent; not in the guides	Vivid dreams and other mild effects

Table 9. Exercise Dosage (12-Week Guideline)

Period	Frequency and duration	Intensity	Examples
Weeks 1-4	2-3 times a week for 20-25 minutes	Low	Timed walking, gentle aerobics, gentle yoga
Weeks 5-8	3 times a week for 25-35 minutes	Low → Moderate	Tai chi, strength training, endurance, breathing practices
Weeks 9-12	3-4 times a week for 30-40 minutes	Moderate, depending on tolerance	Combined training, target-oriented tasks

Prevention

Regular, measured exercise (aerobics + endurance), activity pacing, and a plan for symptom flare-ups. Even small but regular amounts (>100 minutes per week) are associated with improved pain and well-being. [46]

Prioritize sleep: a fixed wake-up time, light in the morning, limited screen time in the evening, and bedtime rituals. Psychoeducation and CBT for pain reduce the risk of chronicity. [47]

Comorbidities – treat, don't tolerate: anxiety/depression, irritable bowel syndrome, orthostatic intolerance. The less "background noise," the quieter the "pain amplifier." [48]

Forecast

Fibromyalgia is a chronic condition, not a progressive "tissue destruction." With an active, multifactorial strategy, most patients achieve clinically significant improvements in function, sleep quality, and mood, even if pain doesn't completely disappear. The key is consistency and realistic expectations: "It's better to live with the same pain" is already a victory. [49]

FAQ

Is this "psychosomatics"?
No. It's a neurobiological disorder of pain processing with central sensitization and often small fiber dysfunction. Psychological factors exacerbate symptoms, but they don't "invent" them. [50]

Is an MRI necessary?
The default is no. Imaging in chronic primary pain does not improve outcomes and is only necessary in cases of "red flags" or suspicion of another pathology (for example, inflammatory back pain). [51]

Which medications actually help?
Amitriptyline, duloxetine/milnacipran, and pregabalin are effective in some patients. The effect is usually moderate; treatment is discussed individually, with non-pharmacological approaches prioritized. NICE does not recommend initiating opioids, non-steroidal anti-inflammatory drugs, or paracetamol for chronic primary pain. [52]

Is low-dose naltrexone a panacea?
No. A large randomized trial from 2024 showed no benefit over placebo for pain; meta-analyses provide conflicting signals. If you try it, only with realistic expectations and monitoring. [53]

What's the most important thing to do yourself?
Pain education, regular, measured activity (including mind-body exercises), sleep, self-regulation skills, and a plan with your doctor for flare-ups. This is more reliable than "miracle treatments." [54]